Clinical Trials
2 trialsNCT05493501 2024-05-02
Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer
EQRx International, Inc.
Phase 3 Terminated
NCT03849768 2023-01-20
A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3 Unknown